Scleroderma Diagnostics and Therapeutics Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2026
N/A
CAGR (2019-2026)
325 USD Mn.
Market Size
306
Report Pages
131
Market Tables
Overview
Global Scleroderma Diagnostics and Therapeutics Market was valued US$ XX Mn in 2018 and is expected to reach US$ 3254.3 Mn by 2026, at CAGR of XX % during forecast period of 2019 to 2026.
To know about the Research Methodology :- Request Free Sample Report
Scleroderma is a chronic and autoimmune disease that affects the body by hardening and tightening of the skin & the connective tissue. Affect to connective tissues by Scleroderma may cause damage to the internal organs such as blood vessels, to thicken causing high blood pressure, damage to heart, and abdomen. Scleroderma results in an allergic reaction, which can also lead to scarring, pain, tissue damage and inflammation.
Scleroderma symptoms is more frequent between age group of 30 and 50 and can be found in men & women but the occurrences of scleroderma in women is four times more compared to men. Scleroderma symptoms vary from person to person.
The exact cause of scleroderma is still unknown. Some Factors like silica exposure, genetic factors, and family history can lead to scleroderma. But the effective treatment with early and accurate diagnosis can mark down the symptoms.
The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.
Global Scleroderma Diagnostics and Therapeutics Market – Overview
Global Scleroderma Diagnostics and Therapeutics Market Dynamics:
For understanding Market dynamics more closely, attributes like Drivers, Restraints, Opportunities, and Challenges are studied more closely in report.
Global Scleroderma Diagnostics and Therapeutics Market Segmentation:
Scleroderma diagnostics and therapeutics market is segmented the market by drug class, indication or by dieses type, by diagnostic test type, and by regions.
The segments of Scleroderma diagnostics and therapeutics market have been studied minutely to get the exact insights based on current as well as coming up trends in the near future on the basis of which the market is estimated from 2018 to 2026. The segment drug type has been further segmented into corticosteroids, immunosuppressive agents, endothelin receptor agonists, calcium channel blockers, PDE-5 inhibitors, chelating agents, and others such as H2 blockers, ACE inhibitors, and proton pump inhibitors.
Scope of Global Scleroderma Diagnostics and Therapeutics Market: Inquire before buying
Segment indication type or dieses type of scleroderma diagnostics and therapeutics market have been sub segmented into localized scleroderma & systemic scleroderma. Segment diagnostic test type, of scleroderma diagnostics and therapeutics market have been segmented into imaging techniques, skin biopsy, electrocardiogram and echocardiogram, pulmonary function tests, and antibodies test /blood test, capillaroscopy, gastrointestinal diagnosis, cardiac diagnosis and general(Electromyography & Dubious diagnostic tests).
The report includes detail information of current and forecasted trend at global, regional and country wise market. Regional part covers for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further segmentation into major countries such as the U.S. Canada, Germany, France, the UK, China, Japan, India, and Brazil.
Global Scleroderma Diagnostics and Therapeutics Market By Drug Type:
The primary cause of scleroderma is still unknown, but extensive research and development activities are ongoing for the Scleroderma Diagnostics and Therapeutics. Early and accurate diagnosis with effective treatment can minimize the adverse effect of Scleroderma. Hence Scleroderma Diagnostics and Therapeutics is segmented by Drug Type.
Under the segmentation Drug Type, it is sub segmented by various drug types, one of them are Corticosteroids. Corticosteroids are used to provide relief for inflamed areas of the body. Corticosteroids lessen swelling, redness, itching, and inflammation. Corticosteroids are often used as part of the treatment for Scleroderma and a number of different diseases too.
Region wise Market Analysis & Forecast:
The report covers a geographic breakdown and a detailed analysis of each of the fore said segments across North America, Europe, Asia Pacific, and LAMEA, and each countries under it –
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Rest of Asia-Pacific
• LAMEA
o Latin America
o Middle East
o Africa
Global Scleroderma Diagnostics and Therapeutics Market Competitive Landscape:
Major players operating in the market are focusing on clinical collaboration and commercial expansion to tap several opportunities present in the market at the same time the company currently focusses on research and development of biologics.
The report supplements, the analysis of market share in order to give a broader overview of key players in the industry, in the scleroderma diagnostics and therapeutics market. Moreover the report also covers research & development, acquisitions & mergers, agreements, partnerships, collaborations & joint ventures, new drug class launch, regional expansion of major participant involved and key strategic developments of the market in the scleroderma diagnostics and therapeutics market across the global as well as country wise basis.
Company Profiles –
Details – Basic Overview, Geographical Presence is illustrated in report. List of key players is mentioned below:
• Actelion Pharmaceuticals, Inc.
• Boehringer Ingelheim
• Bayer AG
• Cytori Therapeutics, Inc.
• Cumberland Pharmaceuticals Inc.
• Gilead Sciences, Inc.
• Pfizer, Inc.
• Active Biotech AB
• BioLineRx, Ltd.
• Bristol-Myers Squibb Company
• Biotech AB,
• Angion Biomedica Corp.,
• Allergan, Inc.,
• Corbus pharmaceuticals, Inc.,
• Digna Biotech,
• Daval International Ltd.,
• F. Hoffmann-La Roche Ltd.,
• Dynavax Technologies Corporation,
• GlaxoSmithKline plc,
• Fibrocell Science, Inc.,
• MedImmune, LLC,
• iBio, Inc.,
• Vida Therapeutics Inc.,
• NovaLead Pharma Pvt. Ltd.
• VivaCell Biotechnology Espana S.L.
Objective of the Report:
The objective of the report is to present a comprehensive analysis of Global Scleroderma Diagnostics and Therapeutics Market including all the stakeholders in the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Scleroderma Diagnostics and Therapeutics Market dynamics, structure by analysing the market segments and project the Global Scleroderma Diagnostics and Therapeutics Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product Portfolio, Growth strategies, and Regional presence in the Global Scleroderma Diagnostics and Therapeutics Market make the report investor’s guide.
Table of Contents
Global Scleroderma Diagnostics and Therapeutics Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Scleroderma Diagnostics and Therapeutics Market Size, by Market Value (US$ Mn )
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast
6.1. Global Scleroderma Diagnostics and Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, By Drug Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Drug Type
7.4. Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Mn ) Forecast, By Drug Type
7.5. Global Scleroderma Diagnostics and Therapeutics Market Analysis, By Drug Type
7.6. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, By Drug Type
8. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, By Indication or by dieses type
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Indication or by dieses type
8.4. Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Mn ) Forecast, By Indication or by dieses type
8.5. Global Scleroderma Diagnostics and Therapeutics Market Analysis, By Indication or by dieses type
8.6. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, By Indication or by dieses type
9. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, By Diagnostic Test Type
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Diagnostic Test Type
9.4. Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Mn ) Forecast, By Diagnostic Test Type
9.5. Global Scleroderma Diagnostics and Therapeutics Market Analysis, By Diagnostic Test Type
9.6. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, By Diagnostic Test Type
10. Global Scleroderma Diagnostics and Therapeutics Market Analysis, by Region
10.1. Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Region
10.2. Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Mn ) Forecast, by Region
10.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Region
11. North America Scleroderma Diagnostics and Therapeutics Market Analysis
11.1. Key Findings
11.2. North America Scleroderma Diagnostics and Therapeutics Market Overview
11.3. North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Drug Type
11.4. North America Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
11.4.1. Corticosteroids
11.4.2. Immunosuppressive Agents
11.4.3. Endothelin Receptor Antagonists
11.4.4. Calcium Channel Blockers
11.4.5. PDE-5 Inhibitors
11.4.6. Chelating Agents
11.4.7. Prostacyclin Analogues
11.4.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
11.5. North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Indication or by dieses type
11.6. North America Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
11.6.1. Localized Scleroderma
11.6.1.1. Morphea
11.6.1.2. Linear Scleroderma
11.6.2. Systemic Scleroderma
11.6.2.1. Diffused Scleroderma
11.6.2.2. Limited Scleroderma
11.7. North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Diagnostic Test Type
11.8. North America Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
11.8.1. Imaging Techniques (CT and MRI)
11.8.2. Skin Biopsy
11.8.3. Electrocardiogram and Echocardiogram
11.8.4. Pulmonary Function Tests
11.8.5. Antibodies Tests / Blood Test
11.8.6. Capillaroscopy
11.8.7. Gastrointestinal Diagnosis
11.8.8. Cardiac Diagnosis
11.8.9. General
11.8.9.1. Electromyography
11.8.9.2. Dubious Diagnostic Tests
11.9. North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country
11.10. North America Scleroderma Diagnostics and Therapeutics Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Scleroderma Diagnostics and Therapeutics Market Analysis, by Country
11.12. U.S. Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
11.12.1. Corticosteroids
11.12.2. Immunosuppressive Agents
11.12.3. Endothelin Receptor Antagonists
11.12.4. Calcium Channel Blockers
11.12.5. PDE-5 Inhibitors
11.12.6. Chelating Agents
11.12.7. Prostacyclin Analogues
11.12.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
11.13. U.S. Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
11.13.1. Localized Scleroderma
11.13.1.1. Morphea
11.13.1.2. Linear Scleroderma
11.13.2. Systemic Scleroderma
11.13.2.1. Diffused Scleroderma
11.13.2.2. Limited Scleroderma
11.14. U.S. Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
11.14.1. Imaging Techniques (CT and MRI)
11.14.2. Skin Biopsy
11.14.3. Electrocardiogram and Echocardiogram
11.14.4. Pulmonary Function Tests
11.14.5. Antibodies Tests / Blood Test
11.14.6. Capillaroscopy
11.14.7. Gastrointestinal Diagnosis
11.14.8. Cardiac Diagnosis
11.14.9. General
11.14.9.1. Electromyography
11.14.9.2. Dubious Diagnostic Tests
11.15. Canada Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
11.15.1. Corticosteroids
11.15.2. Immunosuppressive Agents
11.15.3. Endothelin Receptor Antagonists
11.15.4. Calcium Channel Blockers
11.15.5. PDE-5 Inhibitors
11.15.6. Chelating Agents
11.15.7. Prostacyclin Analogues
11.15.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
11.16. Canada Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
11.16.1. Localized Scleroderma
11.16.1.1. Morphea
11.16.1.2. Linear Scleroderma
11.16.2. Systemic Scleroderma
11.16.2.1. Diffused Scleroderma
11.16.2.2. Limited Scleroderma
11.17. Canada Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
11.17.1. Imaging Techniques (CT and MRI)
11.17.2. Skin Biopsy
11.17.3. Electrocardiogram and Echocardiogram
11.17.4. Pulmonary Function Tests
11.17.5. Antibodies Tests / Blood Test
11.17.6. Capillaroscopy
11.17.7. Gastrointestinal Diagnosis
11.17.8. Cardiac Diagnosis
11.17.9. General
11.17.9.1. Electromyography
11.17.9.2. Dubious Diagnostic Tests
11.18. North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
11.18.1. By Drug Type
11.18.2. By Indication or by dieses type
11.18.3. By Diagnostic Test Type
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments
12. Europe Scleroderma Diagnostics and Therapeutics Market Analysis
12.1. Key Findings
12.2. Europe Scleroderma Diagnostics and Therapeutics Market Overview
12.3. Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Drug Type
12.4. Europe Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
12.4.1. Corticosteroids
12.4.2. Immunosuppressive Agents
12.4.3. Endothelin Receptor Antagonists
12.4.4. Calcium Channel Blockers
12.4.5. PDE-5 Inhibitors
12.4.6. Chelating Agents
12.4.7. Prostacyclin Analogues
12.4.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
12.5. Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Indication or by dieses type
12.6. Europe Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
12.6.1. Localized Scleroderma
12.6.1.1. Morphea
12.6.1.2. Linear Scleroderma
12.6.2. Systemic Scleroderma
12.6.2.1. Diffused Scleroderma
12.6.2.2. Limited Scleroderma
12.7. Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Diagnostic Test Type
12.8. Europe Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
12.8.1. Imaging Techniques (CT and MRI)
12.8.2. Skin Biopsy
12.8.3. Electrocardiogram and Echocardiogram
12.8.4. Pulmonary Function Tests
12.8.5. Antibodies Tests / Blood Test
12.8.6. Capillaroscopy
12.8.7. Gastrointestinal Diagnosis
12.8.8. Cardiac Diagnosis
12.8.9. General
12.8.9.1. Electromyography
12.8.9.2. Dubious Diagnostic Tests
12.9. Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country
12.10. Europe Scleroderma Diagnostics and Therapeutics Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Scleroderma Diagnostics and Therapeutics Market Analysis, by Country
12.12. Germany Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
12.12.1. Corticosteroids
12.12.2. Immunosuppressive Agents
12.12.3. Endothelin Receptor Antagonists
12.12.4. Calcium Channel Blockers
12.12.5. PDE-5 Inhibitors
12.12.6. Chelating Agents
12.12.7. Prostacyclin Analogues
12.12.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
12.13. Germany Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
12.13.1. Localized Scleroderma
12.13.1.1. Morphea
12.13.1.2. Linear Scleroderma
12.13.2. Systemic Scleroderma
12.13.2.1. Diffused Scleroderma
12.13.2.2. Limited Scleroderma
12.14. Germany Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
12.14.1. Imaging Techniques (CT and MRI)
12.14.2. Skin Biopsy
12.14.3. Electrocardiogram and Echocardiogram
12.14.4. Pulmonary Function Tests
12.14.5. Antibodies Tests / Blood Test
12.14.6. Capillaroscopy
12.14.7. Gastrointestinal Diagnosis
12.14.8. Cardiac Diagnosis
12.14.9. General
12.14.9.1. Electromyography
12.14.9.2. Dubious Diagnostic Tests
12.15. U.K. Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
12.15.1. Corticosteroids
12.15.2. Immunosuppressive Agents
12.15.3. Endothelin Receptor Antagonists
12.15.4. Calcium Channel Blockers
12.15.5. PDE-5 Inhibitors
12.15.6. Chelating Agents
12.15.7. Prostacyclin Analogues
12.15.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
12.16. U.K. Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
12.16.1. Localized Scleroderma
12.16.1.1. Morphea
12.16.1.2. Linear Scleroderma
12.16.2. Systemic Scleroderma
12.16.2.1. Diffused Scleroderma
12.16.2.2. Limited Scleroderma
12.17. U.K. Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
12.17.1. Imaging Techniques (CT and MRI)
12.17.2. Skin Biopsy
12.17.3. Electrocardiogram and Echocardiogram
12.17.4. Pulmonary Function Tests
12.17.5. Antibodies Tests / Blood Test
12.17.6. Capillaroscopy
12.17.7. Gastrointestinal Diagnosis
12.17.8. Cardiac Diagnosis
12.17.9. General
12.17.9.1. Electromyography
12.17.9.2. Dubious Diagnostic Tests
12.18. France Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
12.18.1. Corticosteroids
12.18.2. Immunosuppressive Agents
12.18.3. Endothelin Receptor Antagonists
12.18.4. Calcium Channel Blockers
12.18.5. PDE-5 Inhibitors
12.18.6. Chelating Agents
12.18.7. Prostacyclin Analogues
12.18.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
12.19. France Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
12.19.1. Localized Scleroderma
12.19.1.1. Morphea
12.19.1.2. Linear Scleroderma
12.19.2. Systemic Scleroderma
12.19.2.1. Diffused Scleroderma
12.19.2.2. Limited Scleroderma
12.20. France Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
12.20.1. Imaging Techniques (CT and MRI)
12.20.2. Skin Biopsy
12.20.3. Electrocardiogram and Echocardiogram
12.20.4. Pulmonary Function Tests
12.20.5. Antibodies Tests / Blood Test
12.20.6. Capillaroscopy
12.20.7. Gastrointestinal Diagnosis
12.20.8. Cardiac Diagnosis
12.20.9. General
12.20.9.1. Electromyography
12.20.9.2. Dubious Diagnostic Tests
12.21. Italy Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
12.21.1. Corticosteroids
12.21.2. Immunosuppressive Agents
12.21.3. Endothelin Receptor Antagonists
12.21.4. Calcium Channel Blockers
12.21.5. PDE-5 Inhibitors
12.21.6. Chelating Agents
12.21.7. Prostacyclin Analogues
12.21.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
12.22. Italy Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
12.22.1. Localized Scleroderma
12.22.1.1. Morphea
12.22.1.2. Linear Scleroderma
12.22.2. Systemic Scleroderma
12.22.2.1. Diffused Scleroderma
12.22.2.2. Limited Scleroderma
12.23. Italy Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
12.23.1. Imaging Techniques (CT and MRI)
12.23.2. Skin Biopsy
12.23.3. Electrocardiogram and Echocardiogram
12.23.4. Pulmonary Function Tests
12.23.5. Antibodies Tests / Blood Test
12.23.6. Capillaroscopy
12.23.7. Gastrointestinal Diagnosis
12.23.8. Cardiac Diagnosis
12.23.9. General
12.23.9.1. Electromyography
12.23.9.2. Dubious Diagnostic Tests
12.24. Spain Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
12.24.1. Corticosteroids
12.24.2. Immunosuppressive Agents
12.24.3. Endothelin Receptor Antagonists
12.24.4. Calcium Channel Blockers
12.24.5. PDE-5 Inhibitors
12.24.6. Chelating Agents
12.24.7. Prostacyclin Analogues
12.24.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
12.25. Spain Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
12.25.1. Localized Scleroderma
12.25.1.1. Morphea
12.25.1.2. Linear Scleroderma
12.25.2. Systemic Scleroderma
12.25.2.1. Diffused Scleroderma
12.25.2.2. Limited Scleroderma
12.26. Spain Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
12.26.1. Imaging Techniques (CT and MRI)
12.26.2. Skin Biopsy
12.26.3. Electrocardiogram and Echocardiogram
12.26.4. Pulmonary Function Tests
12.26.5. Antibodies Tests / Blood Test
12.26.6. Capillaroscopy
12.26.7. Gastrointestinal Diagnosis
12.26.8. Cardiac Diagnosis
12.26.9. General
12.26.9.1. Electromyography
12.26.9.2. Dubious Diagnostic Tests
12.27. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
12.27.1. Corticosteroids
12.27.2. Immunosuppressive Agents
12.27.3. Endothelin Receptor Antagonists
12.27.4. Calcium Channel Blockers
12.27.5. PDE-5 Inhibitors
12.27.6. Chelating Agents
12.27.7. Prostacyclin Analogues
12.27.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
12.28. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
12.28.1. Localized Scleroderma
12.28.1.1. Morphea
12.28.1.2. Linear Scleroderma
12.28.2. Systemic Scleroderma
12.28.2.1. Diffused Scleroderma
12.28.2.2. Limited Scleroderma
12.29. Rest Of Europe Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
12.29.1. Imaging Techniques (CT and MRI)
12.29.2. Skin Biopsy
12.29.3. Electrocardiogram and Echocardiogram
12.29.4. Pulmonary Function Tests
12.29.5. Antibodies Tests / Blood Test
12.29.6. Capillaroscopy
12.29.7. Gastrointestinal Diagnosis
12.29.8. Cardiac Diagnosis
12.29.9. General
12.29.9.1. Electromyography
12.29.9.2. Dubious Diagnostic Tests
12.30. Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
12.30.1. By Drug Type
12.30.2. By Indication or by dieses type
12.30.3. By Diagnostic Test Type
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments
13. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Analysis
13.1. Key Findings
13.2. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Overview
13.3. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Drug Type
13.4. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
13.4.1. Corticosteroids
13.4.2. Immunosuppressive Agents
13.4.3. Endothelin Receptor Antagonists
13.4.4. Calcium Channel Blockers
13.4.5. PDE-5 Inhibitors
13.4.6. Chelating Agents
13.4.7. Prostacyclin Analogues
13.4.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
13.5. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Indication or by dieses type
13.6. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
13.6.1. Localized Scleroderma
13.6.1.1. Morphea
13.6.1.2. Linear Scleroderma
13.6.2. Systemic Scleroderma
13.6.2.1. Diffused Scleroderma
13.6.2.2. Limited Scleroderma
13.7. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Diagnostic Test Type
13.8. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
13.8.1. Imaging Techniques (CT and MRI)
13.8.2. Skin Biopsy
13.8.3. Electrocardiogram and Echocardiogram
13.8.4. Pulmonary Function Tests
13.8.5. Antibodies Tests / Blood Test
13.8.6. Capillaroscopy
13.8.7. Gastrointestinal Diagnosis
13.8.8. Cardiac Diagnosis
13.8.9. General
13.8.9.1. Electromyography
13.8.9.2. Dubious Diagnostic Tests
13.9. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country
13.10. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Analysis, by Country
13.12. China Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
13.12.1. Corticosteroids
13.12.2. Immunosuppressive Agents
13.12.3. Endothelin Receptor Antagonists
13.12.4. Calcium Channel Blockers
13.12.5. PDE-5 Inhibitors
13.12.6. Chelating Agents
13.12.7. Prostacyclin Analogues
13.12.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
13.13. China Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
13.13.1. Localized Scleroderma
13.13.1.1. Morphea
13.13.1.2. Linear Scleroderma
13.13.2. Systemic Scleroderma
13.13.2.1. Diffused Scleroderma
13.13.2.2. Limited Scleroderma
13.14. China Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
13.14.1. Imaging Techniques (CT and MRI)
13.14.2. Skin Biopsy
13.14.3. Electrocardiogram and Echocardiogram
13.14.4. Pulmonary Function Tests
13.14.5. Antibodies Tests / Blood Test
13.14.6. Capillaroscopy
13.14.7. Gastrointestinal Diagnosis
13.14.8. Cardiac Diagnosis
13.14.9. General
13.14.9.1. Electromyography
13.14.9.2. Dubious Diagnostic Tests
13.15. India Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
13.15.1. Corticosteroids
13.15.2. Immunosuppressive Agents
13.15.3. Endothelin Receptor Antagonists
13.15.4. Calcium Channel Blockers
13.15.5. PDE-5 Inhibitors
13.15.6. Chelating Agents
13.15.7. Prostacyclin Analogues
13.15.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
13.16. India Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
13.16.1. Localized Scleroderma
13.16.1.1. Morphea
13.16.1.2. Linear Scleroderma
13.16.2. Systemic Scleroderma
13.16.2.1. Diffused Scleroderma
13.16.2.2. Limited Scleroderma
13.17. India Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
13.17.1. Imaging Techniques (CT and MRI)
13.17.2. Skin Biopsy
13.17.3. Electrocardiogram and Echocardiogram
13.17.4. Pulmonary Function Tests
13.17.5. Antibodies Tests / Blood Test
13.17.6. Capillaroscopy
13.17.7. Gastrointestinal Diagnosis
13.17.8. Cardiac Diagnosis
13.17.9. General
13.17.9.1. Electromyography
13.17.9.2. Dubious Diagnostic Tests
13.18. Japan Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
13.18.1. Corticosteroids
13.18.2. Immunosuppressive Agents
13.18.3. Endothelin Receptor Antagonists
13.18.4. Calcium Channel Blockers
13.18.5. PDE-5 Inhibitors
13.18.6. Chelating Agents
13.18.7. Prostacyclin Analogues
13.18.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
13.19. Japan Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
13.19.1. Localized Scleroderma
13.19.1.1. Morphea
13.19.1.2. Linear Scleroderma
13.19.2. Systemic Scleroderma
13.19.2.1. Diffused Scleroderma
13.19.2.2. Limited Scleroderma
13.20. Japan Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
13.20.1. Imaging Techniques (CT and MRI)
13.20.2. Skin Biopsy
13.20.3. Electrocardiogram and Echocardiogram
13.20.4. Pulmonary Function Tests
13.20.5. Antibodies Tests / Blood Test
13.20.6. Capillaroscopy
13.20.7. Gastrointestinal Diagnosis
13.20.8. Cardiac Diagnosis
13.20.9. General
13.20.9.1. Electromyography
13.20.9.2. Dubious Diagnostic Tests
13.21. ASEAN Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
13.21.1. Corticosteroids
13.21.2. Immunosuppressive Agents
13.21.3. Endothelin Receptor Antagonists
13.21.4. Calcium Channel Blockers
13.21.5. PDE-5 Inhibitors
13.21.6. Chelating Agents
13.21.7. Prostacyclin Analogues
13.21.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
13.22. ASEAN Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
13.22.1. Localized Scleroderma
13.22.1.1. Morphea
13.22.1.2. Linear Scleroderma
13.22.2. Systemic Scleroderma
13.22.2.1. Diffused Scleroderma
13.22.2.2. Limited Scleroderma
13.23. ASEAN Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
13.23.1. Imaging Techniques (CT and MRI)
13.23.2. Skin Biopsy
13.23.3. Electrocardiogram and Echocardiogram
13.23.4. Pulmonary Function Tests
13.23.5. Antibodies Tests / Blood Test
13.23.6. Capillaroscopy
13.23.7. Gastrointestinal Diagnosis
13.23.8. Cardiac Diagnosis
13.23.9. General
13.23.9.1. Electromyography
13.23.9.2. Dubious Diagnostic Tests
13.24. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
13.24.1. Corticosteroids
13.24.2. Immunosuppressive Agents
13.24.3. Endothelin Receptor Antagonists
13.24.4. Calcium Channel Blockers
13.24.5. PDE-5 Inhibitors
13.24.6. Chelating Agents
13.24.7. Prostacyclin Analogues
13.24.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
13.25. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
13.25.1. Localized Scleroderma
13.25.1.1. Morphea
13.25.1.2. Linear Scleroderma
13.25.2. Systemic Scleroderma
13.25.2.1. Diffused Scleroderma
13.25.2.2. Limited Scleroderma
13.26. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
13.26.1. Imaging Techniques (CT and MRI)
13.26.2. Skin Biopsy
13.26.3. Electrocardiogram and Echocardiogram
13.26.4. Pulmonary Function Tests
13.26.5. Antibodies Tests / Blood Test
13.26.6. Capillaroscopy
13.26.7. Gastrointestinal Diagnosis
13.26.8. Cardiac Diagnosis
13.26.9. General
13.26.9.1. Electromyography
13.26.9.2. Dubious Diagnostic Tests
13.27. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
13.27.1. By Drug Type
13.27.2. By Indication or by dieses type
13.27.3. By Diagnostic Test Type
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments
14. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Overview
14.3. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Drug Type
14.4. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
14.4.1. Corticosteroids
14.4.2. Immunosuppressive Agents
14.4.3. Endothelin Receptor Antagonists
14.4.4. Calcium Channel Blockers
14.4.5. PDE-5 Inhibitors
14.4.6. Chelating Agents
14.4.7. Prostacyclin Analogues
14.4.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
14.5. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Indication or by dieses type
14.6. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
14.6.1. Localized Scleroderma
14.6.1.1. Morphea
14.6.1.2. Linear Scleroderma
14.6.2. Systemic Scleroderma
14.6.2.1. Diffused Scleroderma
14.6.2.2. Limited Scleroderma
14.7. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Diagnostic Test Type
14.8. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
14.8.1. Imaging Techniques (CT and MRI)
14.8.2. Skin Biopsy
14.8.3. Electrocardiogram and Echocardiogram
14.8.4. Pulmonary Function Tests
14.8.5. Antibodies Tests / Blood Test
14.8.6. Capillaroscopy
14.8.7. Gastrointestinal Diagnosis
14.8.8. Cardiac Diagnosis
14.8.9. General
14.8.9.1. Electromyography
14.8.9.2. Dubious Diagnostic Tests
14.9. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country
14.10. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Analysis, by Country
14.12. GCC Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
14.12.1. Corticosteroids
14.12.2. Immunosuppressive Agents
14.12.3. Endothelin Receptor Antagonists
14.12.4. Calcium Channel Blockers
14.12.5. PDE-5 Inhibitors
14.12.6. Chelating Agents
14.12.7. Prostacyclin Analogues
14.12.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
14.13. GCC Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
14.13.1. Localized Scleroderma
14.13.1.1. Morphea
14.13.1.2. Linear Scleroderma
14.13.2. Systemic Scleroderma
14.13.2.1. Diffused Scleroderma
14.13.2.2. Limited Scleroderma
14.14. GCC Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
14.14.1. Imaging Techniques (CT and MRI)
14.14.2. Skin Biopsy
14.14.3. Electrocardiogram and Echocardiogram
14.14.4. Pulmonary Function Tests
14.14.5. Antibodies Tests / Blood Test
14.14.6. Capillaroscopy
14.14.7. Gastrointestinal Diagnosis
14.14.8. Cardiac Diagnosis
14.14.9. General
14.14.9.1. Electromyography
14.14.9.2. Dubious Diagnostic Tests
14.15. South Africa Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
14.15.1. Corticosteroids
14.15.2. Immunosuppressive Agents
14.15.3. Endothelin Receptor Antagonists
14.15.4. Calcium Channel Blockers
14.15.5. PDE-5 Inhibitors
14.15.6. Chelating Agents
14.15.7. Prostacyclin Analogues
14.15.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
14.16. South Africa Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
14.16.1. Localized Scleroderma
14.16.1.1. Morphea
14.16.1.2. Linear Scleroderma
14.16.2. Systemic Scleroderma
14.16.2.1. Diffused Scleroderma
14.16.2.2. Limited Scleroderma
14.17. South Africa Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
14.17.1. Imaging Techniques (CT and MRI)
14.17.2. Skin Biopsy
14.17.3. Electrocardiogram and Echocardiogram
14.17.4. Pulmonary Function Tests
14.17.5. Antibodies Tests / Blood Test
14.17.6. Capillaroscopy
14.17.7. Gastrointestinal Diagnosis
14.17.8. Cardiac Diagnosis
14.17.9. General
14.17.9.1. Electromyography
14.17.9.2. Dubious Diagnostic Tests
14.18. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
14.18.1. Corticosteroids
14.18.2. Immunosuppressive Agents
14.18.3. Endothelin Receptor Antagonists
14.18.4. Calcium Channel Blockers
14.18.5. PDE-5 Inhibitors
14.18.6. Chelating Agents
14.18.7. Prostacyclin Analogues
14.18.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
14.19. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
14.19.1. Localized Scleroderma
14.19.1.1. Morphea
14.19.1.2. Linear Scleroderma
14.19.2. Systemic Scleroderma
14.19.2.1. Diffused Scleroderma
14.19.2.2. Limited Scleroderma
14.20. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
14.20.1. Imaging Techniques (CT and MRI)
14.20.2. Skin Biopsy
14.20.3. Electrocardiogram and Echocardiogram
14.20.4. Pulmonary Function Tests
14.20.5. Antibodies Tests / Blood Test
14.20.6. Capillaroscopy
14.20.7. Gastrointestinal Diagnosis
14.20.8. Cardiac Diagnosis
14.20.9. General
14.20.9.1. Electromyography
14.20.9.2. Dubious Diagnostic Tests
14.21. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
14.21.1. By Drug Type
14.21.2. By Indication or by dieses type
14.21.3. By Diagnostic Test Type
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments
15. South America Scleroderma Diagnostics and Therapeutics Market Analysis
15.1. Key Findings
15.2. South America Scleroderma Diagnostics and Therapeutics Market Overview
15.3. South America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Drug Type
15.4. South America Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
15.4.1. Corticosteroids
15.4.2. Immunosuppressive Agents
15.4.3. Endothelin Receptor Antagonists
15.4.4. Calcium Channel Blockers
15.4.5. PDE-5 Inhibitors
15.4.6. Chelating Agents
15.4.7. Prostacyclin Analogues
15.4.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
15.5. South America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Indication or by dieses type
15.6. South America Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
15.6.1. Localized Scleroderma
15.6.1.1. Morphea
15.6.1.2. Linear Scleroderma
15.6.2. Systemic Scleroderma
15.6.2.1. Diffused Scleroderma
15.6.2.2. Limited Scleroderma
15.7. South America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, By Diagnostic Test Type
15.8. South America Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
15.8.1. Imaging Techniques (CT and MRI)
15.8.2. Skin Biopsy
15.8.3. Electrocardiogram and Echocardiogram
15.8.4. Pulmonary Function Tests
15.8.5. Antibodies Tests / Blood Test
15.8.6. Capillaroscopy
15.8.7. Gastrointestinal Diagnosis
15.8.8. Cardiac Diagnosis
15.8.9. General
15.8.9.1. Electromyography
15.8.9.2. Dubious Diagnostic Tests
15.9. South America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country
15.10. South America Scleroderma Diagnostics and Therapeutics Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Scleroderma Diagnostics and Therapeutics Market Analysis, by Country
15.12. Brazil Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
15.12.1. Corticosteroids
15.12.2. Immunosuppressive Agents
15.12.3. Endothelin Receptor Antagonists
15.12.4. Calcium Channel Blockers
15.12.5. PDE-5 Inhibitors
15.12.6. Chelating Agents
15.12.7. Prostacyclin Analogues
15.12.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
15.13. Brazil Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
15.13.1. Localized Scleroderma
15.13.1.1. Morphea
15.13.1.2. Linear Scleroderma
15.13.2. Systemic Scleroderma
15.13.2.1. Diffused Scleroderma
15.13.2.2. Limited Scleroderma
15.14. Brazil Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
15.14.1. Imaging Techniques (CT and MRI)
15.14.2. Skin Biopsy
15.14.3. Electrocardiogram and Echocardiogram
15.14.4. Pulmonary Function Tests
15.14.5. Antibodies Tests / Blood Test
15.14.6. Capillaroscopy
15.14.7. Gastrointestinal Diagnosis
15.14.8. Cardiac Diagnosis
15.14.9. General
15.14.9.1. Electromyography
15.14.9.2. Dubious Diagnostic Tests
15.15. Mexico Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
15.15.1. Corticosteroids
15.15.2. Immunosuppressive Agents
15.15.3. Endothelin Receptor Antagonists
15.15.4. Calcium Channel Blockers
15.15.5. PDE-5 Inhibitors
15.15.6. Chelating Agents
15.15.7. Prostacyclin Analogues
15.15.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
15.16. Mexico Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
15.16.1. Localized Scleroderma
15.16.1.1. Morphea
15.16.1.2. Linear Scleroderma
15.16.2. Systemic Scleroderma
15.16.2.1. Diffused Scleroderma
15.16.2.2. Limited Scleroderma
15.17. Mexico Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
15.17.1. Imaging Techniques (CT and MRI)
15.17.2. Skin Biopsy
15.17.3. Electrocardiogram and Echocardiogram
15.17.4. Pulmonary Function Tests
15.17.5. Antibodies Tests / Blood Test
15.17.6. Capillaroscopy
15.17.7. Gastrointestinal Diagnosis
15.17.8. Cardiac Diagnosis
15.17.9. General
15.17.9.1. Electromyography
15.17.9.2. Dubious Diagnostic Tests
15.18. Rest of South America Scleroderma Diagnostics and Therapeutics Market Forecast, By Drug Type
15.18.1. Corticosteroids
15.18.2. Immunosuppressive Agents
15.18.3. Endothelin Receptor Antagonists
15.18.4. Calcium Channel Blockers
15.18.5. PDE-5 Inhibitors
15.18.6. Chelating Agents
15.18.7. Prostacyclin Analogues
15.18.8. Others (H2 Blockers, Proton Pump Inhibitors, Ace Inhibitors, and Others)
15.19. Rest of South America Scleroderma Diagnostics and Therapeutics Market Forecast, By Indication or by dieses type
15.19.1. Localized Scleroderma
15.19.1.1. Morphea
15.19.1.2. Linear Scleroderma
15.19.2. Systemic Scleroderma
15.19.2.1. Diffused Scleroderma
15.19.2.2. Limited Scleroderma
15.20. Rest of South America Scleroderma Diagnostics and Therapeutics Market Forecast, By Diagnostic Test Type
15.20.1. Imaging Techniques (CT and MRI)
15.20.2. Skin Biopsy
15.20.3. Electrocardiogram and Echocardiogram
15.20.4. Pulmonary Function Tests
15.20.5. Antibodies Tests / Blood Test
15.20.6. Capillaroscopy
15.20.7. Gastrointestinal Diagnosis
15.20.8. Cardiac Diagnosis
15.20.9. General
15.20.9.1. Electromyography
15.20.9.2. Dubious Diagnostic Tests
15.21. South America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis
15.21.1. By Drug Type
15.21.2. By Indication or by dieses type
15.21.3. By Diagnostic Test Type
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments
16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Actelion Pharmaceuticals, Inc.
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Manufacturing Footprint
16.3.2. Boehringer Ingelheim
16.3.3. Bayer AG
16.3.4. Cytori Therapeutics, Inc.
16.3.5. Cumberland Pharmaceuticals Inc.
16.3.6. Gilead Sciences, Inc.
16.3.7. Pfizer, Inc.
16.3.8. Active Biotech AB
16.3.9. BioLineRx, Ltd.
16.3.10. Bristol-Myers Squibb Company
16.3.11. Biotech AB,
16.3.12. Angion Biomedica Corp.,
16.3.13. Allergan, Inc.,
16.3.14. Corbus pharmaceuticals, Inc.,
16.3.15. Digna Biotech,
16.3.16. Daval International Ltd.,
16.3.17. F. Hoffmann-La Roche Ltd.,
16.3.18. Dynavax Technologies Corporation,
16.3.19. GlaxoSmithKline plc,
16.3.20. Fibrocell Science, Inc.,
16.3.21. MedImmune, LLC,
16.3.22. iBio, Inc.,
16.3.23. Vida Therapeutics Inc.,
16.3.24. NovaLead Pharma Pvt. Ltd.
16.3.25. VivaCell Biotechnology Espana S.L
17. Primary Key Insights